We are pleased to announce J-Pharmaʼs lead oncology product candidate, Nanvuranlat will feature at the upcoming ASCO Gastrointestinal Cancers Symposium, to be held in San Francisco on 19-21 January 2023
2022-12-23 · J-Pharma Co., Ltd. · original j-pharma.com ↗
December 23,2022 J-Pharma Co., Ltd. We are pleased to announce J-Pharmaʼs lead oncology product candidate, Nanvuranlat will feature at the upcoming ASCO Gastrointestinal Cancers Symposium, to be held in San Francisco on 19-21 January 2023. Presentation Details: Rapid Abstract Session B: Rapid Abstract Session B: Date/Time: January 20,2023 7:10 -7:15 am PST Place: Level 3, Ballroom Poster Session Date/Time: January 20,2023 12:00 – 13:30 pm PST Place: Level 1, West Hall Abstract Number: 494 Abstract Title: Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study Contact: Tomohiro Yuzawa, Director, Corporate Management Tel: 045-506-1155 [email protected]
The release as fetched from its publisher. j-pharma.com ↗